At the American Heart Association Scientific Sessions 2021 (November 13-15), investigators presented latest data from clinical trials of novel agents targeting hypertriglyceridaemia and atherogenic risk, and provided new insights into the role of apoB-containing lipoproteins in myocardial infarction.
Reportage by Jenny Bryan